<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PSA Rising Prostate Cancer Blog &#187; Metastatic</title>
	<atom:link href="http://www.psa-rising.com/blog/category/pca/metastatic/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.psa-rising.com/blog</link>
	<description></description>
	<lastBuildDate>Wed, 25 Nov 2009 18:36:49 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.6</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Degarelix Effect Compared to Lupron</title>
		<link>http://www.psa-rising.com/blog/2008/12/degarelix-effect-compared-to-lupron/</link>
		<comments>http://www.psa-rising.com/blog/2008/12/degarelix-effect-compared-to-lupron/#comments</comments>
		<pubDate>Sat, 27 Dec 2008 10:26:26 +0000</pubDate>
		<dc:creator>jacquie strax</dc:creator>
				<category><![CDATA[Hormonal-ADT]]></category>
		<category><![CDATA[Metastatic]]></category>
		<category><![CDATA[PCa Treatments]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[degarelix]]></category>

		<guid isPermaLink="false">http://www.psa-rising.com/blog/?p=825</guid>
		<description><![CDATA[Below are a graph and a table of the effect of Ferring&#8217;s degarelix on testosterone compared with the effect of Lupron. On December 24th Ferring announced that FDA has approved degarelix for the treatment of hormonally sensitive advanced prostate cancer.
Degarelix (generic name) is a GnRH receptor antagonist. The company says: &#8220;Degarelix achieves medical castration differently [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2008/12/degarelix-effect-compared-to-lupron/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Ambrilia&#8217;s peptide for metastatic prostate cancer, Phase I/II results</title>
		<link>http://www.psa-rising.com/blog/2007/04/amrilias-peptide-drug-for-metastic-prostate-cancer-phase-iii-results/</link>
		<comments>http://www.psa-rising.com/blog/2007/04/amrilias-peptide-drug-for-metastic-prostate-cancer-phase-iii-results/#comments</comments>
		<pubDate>Tue, 24 Apr 2007 10:19:53 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Clinical trials]]></category>
		<category><![CDATA[Metastatic]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[Ambrilia]]></category>
		<category><![CDATA[PCK3145]]></category>

		<guid isPermaLink="false">http://psa-rising.com/blog/index.php/2007/04/24/amrilias-peptide-drug-for-metastic-prostate-cancer-phase-iii-results/</guid>
		<description><![CDATA[Ambrilia, a Montreal company, said today that results of a Phase I/II trial  of PCK3145 in  patients with metastatic prostate  cancer show  that the drug, a small molecule  peptide, slows tumor doubling time.. 
Previously, detailed Phase I  results were presented at ASCO and are online: Slovin, S., et al. [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2007/04/amrilias-peptide-drug-for-metastic-prostate-cancer-phase-iii-results/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
